Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.34 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.34 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.34 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.34 |
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 3/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | RXRB | P28702 | 1/20 | 0.33 |
| ▸ | RXRG | P48443 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12697445 | 1.00 | SCN9A (0.40) | SCN9AMEN1HTTKMT2AKCNQ3 | |
| SCHEMBL12563392 | 0.89 | SCN9A (0.38) | SCN9AMEN1HTTKMT2AIDO1 | |
| SCHEMBL1661095 | 0.88 | KCNQ3 (0.33) | SCN9AKCNQ3KCNQ2KCNQ4KCNQ5 | |
| SCHEMBL12521197 | 0.88 | SCN9A (0.38) | SCN9AMEN1HTTKMT2AIDO1 | |
| SCHEMBL1660607 | 0.87 | PDE2A (0.36) | KCNQ3KCNQ2KCNQ4KCNQ5PDE2A | |
| SCHEMBL12604717 | 0.87 | PDE2A (0.36) | KCNQ3KCNQ2KCNQ4KCNQ5PDE2A | |
| SCHEMBL12604702 | 0.86 | KCNQ3 (0.34) | KCNQ3KCNQ2KCNQ4KCNQ5PDE2A | |
| SCHEMBL1988476 | 0.86 | KCNQ3 (0.34) | KCNQ3KCNQ2KCNQ4KCNQ5PDE2A | |
| SCHEMBL12605015 | 0.85 | PDE2A (0.36) | KCNQ3KCNQ2KCNQ4KCNQ5PDE2A | |
| SCHEMBL1986580 | 0.85 | PDE2A (0.36) | KCNQ3KCNQ2KCNQ4KCNQ5PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110152318-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2011-06-23 | — | — | US | claimed |
| EP-2509793-A1 | MARKING BASED ON MODIFIED CHIRAL LIQUID CRYSTAL POLYMERS | SICPA Holding SA (CH) | 2012-10-17 | — | — | EP | disclosed |
| US-20110152318-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2011-06-23 | — | — | US | disclosed |
| WO-2011069692-A1 | MARKING BASED ON MODIFIED CHIRAL LIQUID CRYSTAL POLYMERS | SICPA HOLDING SA (CH) | 2011-06-16 | — | — | WO | disclosed |
| EP-2307394-A2 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Amorepacific Corporation (KR) | 2011-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152318-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | TRPV1, TRPA1, TRPV2 | SCN9A 262/4885MEN1 1228/4885HTT 2827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.